Shire (SHP) Given Overweight Rating at JPMorgan Chase & Co.
A number of other equities analysts have also recently commented on SHP. Liberum Capital reaffirmed a buy rating and set a GBX 4,200 ($56.96) price target on shares of Shire in a research note on Monday, November 20th. Citigroup reaffirmed a buy rating and set a GBX 5,500 ($74.59) price target on shares of Shire in a research note on Friday, January 5th. Kepler Capital Markets reaffirmed a buy rating and set a GBX 4,600 ($62.38) price target on shares of Shire in a research note on Wednesday, November 1st. Royal Bank of Canada reaffirmed an outperform rating on shares of Shire in a research note on Friday, November 17th. Finally, Berenberg Bank lifted their price target on shares of Shire from GBX 5,900 ($80.01) to GBX 6,000 ($81.37) and gave the stock a buy rating in a research note on Monday, November 6th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of GBX 5,152.94 ($69.88).
Shire (LON SHP) opened at GBX 3,581 ($48.56) on Wednesday. Shire has a 52 week low of GBX 3,435.50 ($46.59) and a 52 week high of GBX 5,067 ($68.71). The company has a market cap of $32,500.00 and a PE ratio of 2,733.59.
In other Shire news, insider Dominic Blakemore purchased 165 shares of Shire stock in a transaction dated Tuesday, December 19th. The stock was acquired at an average price of GBX 3,790 ($51.40) per share, for a total transaction of £6,253.50 ($8,480.47).
COPYRIGHT VIOLATION WARNING: “Shire (SHP) Given Overweight Rating at JPMorgan Chase & Co.” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/shire-shp-given-overweight-rating-at-jpmorgan-chase-co/1806474.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.